Hydroxyethyl starches: Different products - different effects

Anesthesiology

Volumn 111, Issue 1, 2009, Pages 187-202

  Westphal, Martin ^a   James, Michael F M ^b   Kozek Langenecker, Sibylle ^c   Stocker, Reto ^d   Guidet, Bertrand ^e   Van Aken, Hugo ^c  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d University Hospital Zurich Switzerland   (France)

^e HÔPITAL SAINT ANTOINE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BILIRUBIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; HETASTARCH; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; INTERLEUKIN 8; UNCLASSIFIED DRUG; VOLULYTE;

AREA UNDER THE CURVE; BILIRUBIN BLOOD LEVEL; BIOEQUIVALENCE; BLEEDING; BLOOD CLOTTING; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; ENDOTHELIUM; FLUID RESUSCITATION; HUMAN; HYPERCHLOREMIA; HYPERCHLOREMIC METABOLIC ACIDOSIS; INFLAMMATION; KIDNEY FUNCTION; MAIZE; MAJOR SURGERY; MAXIMUM PLASMA CONCENTRATION; METABOLIC ACIDOSIS; MICROCIRCULATION; MOLECULAR WEIGHT; POTATO; PRIORITY JOURNAL; REVIEW; THROMBOCYTE FUNCTION; TISSUE OXYGENATION; VOLUNTEER;

EID: 67650081547     PISSN: 00033022     EISSN: 15281175     Source Type: Journal    
DOI: 10.1097/ALN.0b013e3181a7ec82     Document Type: Review

References (140)

1. Holte K, Kehlet H: Fluid therapy and surgical outcomes in elective surgery: A need for reassessment in fast-track surgery. J Am Coll Surg 2006; 202:971-89
2. Rivers E, Nguyen B, Havstad S, ResslerJ, Muzzin A, Knoblich B, Peterson E, Tomlanovich M: Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001; 345:1368-77
3. DellingerRP, Levy MM, CarletJM, BionJ, Parker MM, Jaeschke R, Reinhart K, Angus D, Brun-Buisson C, Beale R, Calandra T, Dhainaut J, Gerlach H, Harvey M, MariniJ, Marshall J, Ranieri M, Ramsay G, SevranskyJ, Thompson B, Townsens S, Vender J, Zimmerman J, Vincent J: Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008; 36:296-327
4. Brandstrup B: Fluid therapy for the surgical patient. Best Pract Res Clin Anaesthesiol 2006; 20:265-83
5. GanTJ, SoppittA, MaroofM, el-MoalemH, RobertsonKM, MorettiE, Dwane D, Glass PS: Goal-directed intraoperative fluid administration reduces length of hospital stay after major surgery. ANESTHESIOLOGY 2002; 97:820-6
6. Boldt J: Pro: Use of colloids in cardiac surgery. J Cardiothorac Vasc Anesth 2007; 21:453-6
7. Lehmann G, Asskali F, Forster H: Pharmacokinetics of hydroxyethyl starch (70/0.5) following repeated infusions. Transfuse Med Hemother 2003; 30:72-7
8. Asskali F, Forster HL: The accumulation of different substituted hydroxy ethyl starches (HES) following repeated infusions in healthy volunteers. Anast- haesiol Intens Notfall Schmerz 1999; 34:537-41
9. Yoshida M, Minami Y, Kishikawa T: A study of hydroxyethyl-starch: Part III. Comparison ofmetabolic fates between 2-0-hydroxyethyl starch and 6-0-hydroxy- ethyl starch in rabbits. Staorke 1984; 36:209-12
10. Jung F, Koscielny J, Mrowietz C, Forster H, Schimetta W, Kiesewetter H, Wenzel E: The effect of molecular structure of hydroxyethyl starch on the elimination kinetics and fluidity of blood in human volunteers. Arzneimittelfors-chung 1993; 43:99-105
11. Treib J, Haass A, Pindur G, Seyfert U, Treib W, Grauer M, JungF, Wenzel E, Schimrigk K: HES 200/0.5 is not HES 200/0.5. Influence of the C2/C6 hydroxy-ethylation ratio of hydroxyethyl starch (HES) on hemorheology, coagulation and elimination kinetics. Thromb Haemost 1995; 74:1452-6
12. Weidler B, von Bormann B, Sommermeyer K, Lohmann E, Peil J, Hempel- mann G: Pharmacokinetic parameters as criteria for clinical use of hydroxyethyl starch preparations. Arzneimittelforschung 1991; 41:494-8
13. Wilkes NJ, Woolf RL, Powanda MC, Gan TJ, Machin SJ, Webb A, Mutch M, Bennett-Guerrero E, Mythen M: Hydroxyethyl starch in balanced electrolyte solution (Hextend®) - Pharmacokinetic and pharmacodynamic profiles in healthy volunteers. Anesth Analg 2002; 94:538-44
14. Yacobi A, Stoll RG, Sum CY, Lai C-M, Gupta SD, Hulse JD: Pharmacokinet- ics ofhydroxyethyl starch in normal subjects. J Clin Pharmacol 1982; 22:206-12
15. Mishler JM, Borberg H, Emerson PM, Gross R: Hydroxyethyl starch: An agent for hypovolemic shock treatment. J Surg Res 1977; 23:239-45
16. Kooltringer P, Pfeiffer K, Lind P, Wakonig P, Langsteger W, Eber o, Re- isecker F: Haemodilution with medium molecular weight hydroxyethylstarch 6%HES 200,000/0.60 - 0.66 in patients with peripheral arterial disease. ost Kran kenhauspharmazie 1989; 8:7-12
17. Treib J, Haass A, Pindur G, Treib W, Wenzel E, Schimrigk K: Influence of intravascular molecular weight of hydroxyethyl starch on platelets. Eur J Haema- tol 1996; 56:168-72
18. Kroomer H, Haass A, Muoller K, Jaoger H, Wagner E, Heimburg P, Klotz U: Haemodilution therapy in ischaemic stroke: Plasma concentrations and plasma viscosityduringlong-terminfusionofdextran40 orhydroxyethylstarch 200/0.5.Eur J Clin Pharmacol 1987; 31:705-10
19. Waitzinger J, Bepperling F, Pabst G, opitz J, Muoller M, Baron J: Pharma- cokinetics and tolerability of a new hydroxyethyl starch (HES) specification [HES(130/0.4)] after single-dose infusion of 6% or 10% solutions in healthy volunteers. Clin Drug Investig 1998; 16:151-60
20. Waitzinger J, Bepperling F, Pabst G, opitz J: Hydroxyethyl starch (HES) [130/0.4], a new HES specification. Pharmacokinetics and safety after multiple infusions of 10% solution in healthy volunteers. Drugs RD 2003; 4:149-57
21. Jungheinrich C: The starch family: Are they all equal? Pharmacokinetics and pharmacodynamics of hydroxyethyl starches. Transfus Altern Transfus Med 2007; 9:152-63
22. Jungheinrich C, Sauermann W, Bepperling F, Vogt N: Volume efficacy and reduced influence on measures of coagulation using hydroxyethyl starch 130/0.4 (6%) with an optimised in vivo molecular weight in orthopaedic surgery. Drugs RD 2004; 5:1-9
23. Metcalf W, Papadopoulos A, Tufaro R, Barth A: A clinical physiologic study of hydroxyethyl starch. Surg Gynecol obstet 1970; 131:255-67
24. Koohler H, Kirch W, Klein H, Distler A: The effect of 6% hydroxyethyl starch450/0.7, 10% dextranand3.5% gelatine onplasmavolume inpatientswith terminal renal insufficiency. Anaesthesist 1978; 27:421-6
25. Ickx BE, Bepperling F, Melot C, Schulman C, van der Linden PJ: Plasma substitution effects of a new hydroxyethyl starch HES 130/0.4 compared with HES 200/0.5 duringandafterextendedacute normovolaemic haemodilution. BrJ Anaesth 2003; 91:196-202
26. Boldt J, Lehmann A, Roompert R, Haisch G, Isgro F: Volume therapy with a new hydroxyethyl starch solution in cardiac surgical patients before cardiopul- monary bypass. J Cardiothorac Vasc Anesth 2000; 14:264-8
27. Kasper SM, Stroomich A, Kampe S, Radbruch L: Evaluation of a new hydroxyethyl starch solution (HES 130/0.4) in patients undergoing preoperative autologous blood donation. J Clin Anesth 2001; 13:486-90
28. Jacob M, Rehm M, orth V, Lootsch M, Brechtelsbauer H, Weninger E, Finsterer U: Exact measurement of the volume effect of 6% hydroxyethyl starch 130/0.4 (Voluven) during acute preoperative normovolemic hemodilution. An- aesthesist 2003; 52:896-904
29. James MF, Latoo MY, Mythen MG, Mutch M, Michaelis C, Roche AM, Burdett E: Plasma volume changes associated with two hydroxyethyl starch colloids following acute hypovolaemia in volunteers. Anaesthesia 2004; 59:738-42
30. Gandhi SD, Weiskopf RB, Jungheinrich C, Koorn R, Miller D, Shangraw RE, Prough DS, Baus D, Bepperling F, Waritier DC: Volume replacement therapy during major orthopaedic surgery using Voluven (hydroxyethyl starch 130/0.4)or hetastarch. ANESTHESIOLOGY 2007; 106:1120-7
31. Gallandat Huet RC, Siemons AW, Baus D, van Rooyen-Butijn WT, Haa- genaars JA, van oeveren W, Bepperling F: A novel hydroxyethyl starch (Volu- ven®) for effective perioperative plasma volume substitution in cardiac surgery. Can J Anaesth 2000; 47:1207-15
32. Langeron O, Doelberg M, Ang E-T, Bonnet F, Capdevila X, Coriat P: Voluven®, a lower substituted novel hydroxyethyl starch (HES 130/0.4) causes fewer effects on coagulation in major orthopaedic surgery than HES 200/0.5.Anesth Analg 2001; 92:855-62
33. Sommermeyer K, Cech F, Schossow R: Differences in chemical structures between waxy maize- and potato-starch-based hydroxyethyl starch volume therapeutics. Transfus Altern Transfus Med 2007; 9:127-33
34. Lehmann G, Marx G, Foorster H: Bioequivalence comparison between hydroxyethyl starch 130/0.42/6:1 and hydroxyethyl starch 130/0.4/9:1. Drugs RD 2007; 8:229-40
35. Singh N, Singh J, Kaur L, Sodhi NS, Gill BS: Morphological, thermal and rheological properties of starches from different botanical sources. Food Chem 2003; 81:219-31
36. Blennow A, Bay-Smidt AM, Olsen CE, M0ller BL. The distribution of covalently bound phosphate in the starch granule in relation to starch crystal-linity. Int J Biol Macromol 2000; 27:211-8
37. MacIntyre E, Mackie IJ, Ho D, Tinker J, Bullen C, Machin SJ: The haemostatic effects of hydroxyethyl starch (HES) used as a volume expander. Intensive Care Med 1985; 11:300-3
38. Claes Y, van Hemelrijck J, van Gerven M, Arnout J, Vermylen J, Weider B, Van Aken H: Influence of hydroxyethyl starch on coagulation in patients during the perioperative period. Anesth Analg 1992; 75:24-30
39. Kozek-Langenecker S. Effects of hydroxyethyl starch solutions on hemo- stasis. ANESTHESIOLOGY 2005; 103:654-60
40. De Jonge E, Levi M, Buoller HR, Berends F, Kasecioglu J: Decreased circu-latinglevelsofvonWillebrandfactorafterintravenous administrationofa rapidly degradable hydroxyethyl starch (HES 200/0.5/6) in healthy human subjects.Intensive Care Med 2001; 27:1825-9
41. Jamnicki M, Bombeli T, Seifert B, Zollinger A, Camenzind V, Pasch T, Spahn D: Low- and medium-molecular-weight hydroxyethyl starches: Comparison of their effect on blood coagulation. ANESTHESIOLOGY 2000; 92:1231-7
42. Kapiotis S, Quehenberger P, Eichler H, Scharzinger I, Partan C, Schneider B, Lechner K, Speiser W: Effect of hydroxyethyl starch on the activity of blood coagulation and fibrinolysis in healthy volunteers: Comparison with albumin. Crit Care Med 1994; 22:606-12
43. Jones SB, Whitten CW, Despotis GJ, Monk TG: The influence of crystalloid and colloid replacement solutions in acute normovolemic hemodilution: A preliminary survey of hemostatic markers. Anesth Analg 2003; 96:363-8
44. Conroy JM, Fishman RL, Reeves ST, Pinsoky ML, Lazarchick J: The effects of desmopressin and 6% hydroxyethyl starch on factor VIIIC. Anesth Analg 1996;83:804-7
45. Franz A, Broaunlich P, Gamsjoager T, Felfernig M, Gustorff B, Kozek-Lange- necker SA: The effects of hydroxyethyl starches of varying molecular weights on platelet function. Anesth Analg 2001; 92:1402-7
46. Entholzner EK, Mielke LL, Calatzis AN, Feyh J, Hipp R, Hargasser SR: Coagulation effects of a recently developed hydroxyethyl starch (HES 130/0.4) compared to hydroxyethyl starches with higher molecular weight. Acta Anaes-thesiol Scand 2000; 44:1116-21
47. KonradCJ,MarklTJ, SchuepferGK, SchmeckJ, GerberHR: In vitro effects of different medium molecular hydroxyethyl starch solutions and lactated Ringer's solution on coagulation using SONOCLOT. Anesth Analg 2000; 90:274-9
48. Jamnicki M, Zollinger A, Seifert B, Popovic D, Pasch T, Spahn DR: Compromised blood coagulation: An in vitro comparison of hydroxyethyl starch 130/0.4 and hydroxyethyl starch 200/0.5 using thromboelastography. Anesth Analg 1998; 87:989-93
49. Deusch E, Thaler U, Kozek-Langenecker SA: The effects ofhigh molecular weight hydroxyethyl starch solutions on platelets. Anesth Analg 2004; 99:665-8
50. Neff TA, Doelberg M, Jungheinrich C, Sauerland A, Spahn DR, Stocker R: Repetitive large-dose infusion of the novel hydroxyethyl starch 130/0.4 in patients with severe head injury. Anesth Analg 2003; 96:1453-9
51. EllgerB, FreyhoffJ, VanAkenH, Booke M, Markus MA: High dose volume replacementusingHES 130/0.4 duringmajorsurgery. Impactoncoagulationand incidence of postoperative itching. Neth Tijdschr Anesth 2006; 19:63-8
52. Kasper SM, Meinert P, Kampe S, GoergC, Geisen C, Mehlhorn U, Diefen- bach C: Large-dose hydroxyethyl starch 130/0.4 does not increase blood loss and transfusion requirements in coronary artery bypass surgery compared with hy- droxyethyl starch 200/0.5 at recommended doses. ANESTHESIOLOGY 2003; 99:42-7
53. Kozek-Langenecker SA, Jungheinrich C, Sauermann W, van der Linden PJ: The effects of hydroxyethyl starch 130/0.4 (6%) on blood loss and use of blood products in major surgery: A pooled analysis of randomized clinical trials. Anesth Analg 2008; 107:382-90
54. Kozek-Langenecker SA, Jungheinrich C, Sauermann W, van der Linden PJ: Hydroxyethyl starch 130/0.4 reduces blood loss in majorsurgery. Intensive Care Med 2006; 32:S2-17
55. Cheng D, Belisle S, Giffin M, Karkouti K, Martin J, James M, Laliberte P, McCluskey S, Muirhead B, Pendergrast J, Sharpe M, Waters T: Colloids for perioperative plasma volume expansion: Systematic review with meta-analysis of controlled trials (Abstract). Transfus Altern Transfus Med 2007; 9:S3
56. Sander o, Reinhart K, Meier-Helmann A: Equivalence of hydroxyethyl starch HES 130/0.4 and HES 200/0.5 for perioperative volume replacement in major gynaecological surgery. Acta Anaesthesiol Scand 2003; 47:1151-8
57. Stander S, Szepfalusi Z, Bohle B, Stander H, Kraft D, Luger T, Metze D: Differentialstorage ofhydroxyethylstarch(HES)inthe skin: Animmunoelectron- microscopical long-term study. Cell Tissue Res 2001; 304:261-9
58. Reimann S, Szeepfalusi Z, Kraft D, Luger T, Metze D: Hydroxyethyl starch accumulation in the skin with special reference to hydroxyethyl starch-associated pruritus. Dtsch Med Wochenschr 2000; 125:280-5
59. Pfeifer U, Kult J, Foarster H: Ascites as a complication ofhepatic storage of hydroxyethyl starch in long-term dialysis. Klin Wochenschr 1984; 62:862-6
60. Dienes HP, Gerharz CD, Wagner R, Weber M, John HD: Accumulation of hydroxyethyl starch (HES) in the liver of patients with renal failure and portal hypertension. J Hepatol 1986; 3:223-7
61. Jesch F, Huabner G, Zumtobel V, Zimmermann M, Messmer K: Hydroxy- ethyl starch (HAS 450/0.7) in human plasma and liver. Course ofconcentration and histological changes. Infusionsther Klin Ernahr 1979; 6:112-7
62. Metze D, Reimann S, Szeepfalusi Z, Bohle B, Kraft D, Luger T: Persistent pruritus after hydroxyethyl starch infusion therapy: A result of long-term storage in cutaneous nerves. Br J Dermatol 1997; 136:553-9
63. Jurecka W, Szepfalusi Z, Parth E, Schimetta W, Gebhart W, Scheiner O,Kraft D: Hydroxyethylstarch deposits in human skin - a model for pruritus? Arch Dermatol Res 1993; 285:13-9
64. Cox NH, Popple AW: Persistent erythema and pruritus, with a confluent histiocytic skin infiltrate, following the use of a hydroxyethylstarch plasma expander. Br J Dermatol 1996; 134:353-7
65. Heilmann L, Lorch E, Hojnacki B, Munterfering H, Forster H: Accumulation of two different hydroxyethyl starch preparations in the placenta after hemodi- lution in patients with fetal intrauterine growth retardation or pregnancy hypertension. Infusionstherapie 1991; 18:236-43
66. Stander S, Bone HG, Machens HG, Aberle T, Burchard W, Prien T, Luger TA, Metze D: Hydroxyethyl starch does not cross the blood-brain or the placental barrier but the perineurium of peripheral nerves in infused animals. Cell Tissue Res 2002; 310:279-87
67. Leuschner J, Opitz J, Winkler A, ScharpfR, Bepperling F: Tissue storage of 14C-labelled hydroxyethyl starch (HES) 130/0.4 and HES 200/0.5 after repeated intravenous administration to rats. Drugs RD 2003; 4:331-8
68. Hulse J, Yacobi A: Hetastarch: An overview of the colloid and its metabolism. Drug Intell Clin Pharm 1983; 17:334-41
69. Barron ME, Wilkes MW, Navickis RJ: A systematic review of the comparative safety of colloids. Arch Surg 2004; 139:552-63
70. Sirtl C, Laubenthal H, Zumtobel V, Kraft D, Jurecka W: Tissue deposits of hydroxyethyl starch (HES): Dose-dependent and time-related. Br J Anaesth 1999;82:510-5
71. Murphy M, Carmichael AJ, Lawler PG, White M, Cox NH: The incidence of hydroxyethyl starch-associated pruritus. Br J Dermatol 2001; 144:973-6
72. Gall H, Schultz KD, Boahncke WH, Kaufmann R: Clinical and pathophysi-ological aspects ofhydroxyethyl starch-induced pruritus: Evaluation of96 cases.Dermatology 1996; 192:222-6
73. Desloovere C, Knecht R: Infusion therapy in sudden deafness. Reducing the risk of pruritus after hydroxyethyl starch and maintaining therapeutic success-A prospective randomized study. Laryngorhinootologie 1995; 74:468-72
74. Bork K: Pruritus precipitated by hydroxyethyl starch: A review. Br JDermatol 2005; 152:3-12
75. Klemm E, Bepperling F, Burschka MA, Moasges R: Hemodilution therapy with hydroxyethyl starch solution (130/0.4) in unilateral idiopathic sudden sensorineural hearing loss: A dose-finding, double-blind, placebo-controlled, international multicenter trial with 210 patients. Otol Neurotol 2007; 28:157-70
76. Van der Linden PJ, de Hert SG, Deraedt D, Cromheecke S, de Decker K, de Paep R, Rodrigus I, Daper A, Trenchant A: Hydroxyethyl starch 130/0.4 versus modified fluid gelatin for volume expansion in cardiac surgery patients: The effects on perioperative bleeding and transfusion needs. Anesth Analg 2005; 101:629-34
77. Rudolf J: Hydroxyethyl starch for hypervolemic hemodilution in patients with acute ischemic stroke: A randomized, placebo-controlled phase II safety study. Cerebrovasc Dis 2002; 14:33-41
78. Woessner R, Grauer MT, Dieterich H-J, Bepperling F, Baus D, Kahles T, Georgi S, Bianchi O, MorgenthalerM, TreibJ: Influence of along-term, high-dose volume therapy with 6% hydroxyethyl starch 130/0.4 or crystalloid solution on hemodynamics, rheology and hemostasis in patients with acute ischemic stroke. Pathophysiol Haemost Thromb 2003; 33:121-6
79. Legendre C, Thervet E, B, Percheron A, Noel L, Kreis H: Hydroxy- ethylstarch and osmotic-nephrosis-like lesions in kidney transplantation. Lancet 1993; 342:238-9
80. Cittanova ML, Leblanc I, Legendre C, Mouquet C, Riou B, Coriat P: Effect of hydroxyethyl starch in brain-dead kidney donors on renal function in kidney- transplant recipients. Lancet 1996; 348:1620-2
81. Deman A, Peeters P, Sennesael J: Hydroxyethyl starch does not impair immediate renal function in kidney transplant recipients: A retrospective, multi- centre analysis. Nephrol Dial Transplant 1999; 14:1517-20
82. Kumle B, Boldt J, Piper S, Schmidt C, Suttner S, Salopek S: The influence of different intravascular volume replacement regimens on renal function in the elderly. Anesth Analg 1999; 89:1124-30
83. Dehne M, Muhling J, Sablotzki A, Dehne K, Sucke N, Hempelmann G: Hydroxyethyl starch (HES) does not directly affect renal function in patients with no prior renal impairment. J Clin Anesth 2001; 13:103-11
84. Schortgen F, Lacherade JC, Bruneel F, Cattaneo I, Hemery F, Lemaire F, Brochard L: Effects of hydroxyethyl starch and gelatine on renal function in severe sepsis: A multicentre randomised study. Lancet 2001; 357:911-6
85. Winkelmayer WC, Glynn RJ, Levin R, Avorn J: Hydroxyethyl starch and change in renal function in patients undergoing coronary artery bypass graft surgery. Kidney Int 2003; 64:1046-9
86. Boldt J, Brosch C, Roahm K, Papsdorf M, Mengistu A: Comparison of the effects of gelatin and a modern hydroxyethyl starch solution on renal function and inflammatory response in elderly cardiac surgery patients. Br J Anaesth 2008 100:457-64
87. Boldt J, Brosch C, Roahm K, Lehmann A, Mengistu A, Suttner S: Is albumin administration in hypoalbuminemic elderly cardiac surgery patients of benefit with regard to inflammation, endothelial activation, and long-term kidney function? Anesth Analg 2008; 107:1496-503
88. Sakr Y, Payen D, Reinhart K, Sipmann F, Zavala E, Bewley J, Marx G, Vincent J: Effects of hydroxyethyl starch administration on renal function in critically ill patients. Br J Anaesth 2007; 98:216-24
89. Brunkhorst FM, Engel C, Bloos F, Meier-Hellmann A, Ragaller M, Weiler N, Moerer O, Gruendling M, Oppert M, Grond S, Olthoff D, Jaschinksi U, John S, Rossaint R, Welte T, Schaefer M, Kern P, Kuhnt E, Kiehntopf M, Hartog C,Natanson C, Loeffler M, Reinhart K: Intensive insulin therapy and pentastarch resuscitation in severe sepsis. New Eng J Med 2008; 358:125-39
90. Hussain SF, Drew PJ: Acute renal failure after infusion of gelatins. BMJ1989; 299:1137-8
91. Vos SC, Hage JJ, Woerdeman LA, Noordanus RP: Acute renal failure during dextran-40 antithrombotic prophylaxis: Report of two microsurgical cases. Ann Plast Surg 2002; 48:193-6
92. Rozich JD, Paul RV: Acute renal failure precipitated by elevated colloid osmotic pressure. Am J Med 1989; 87:359-60
93. Bartels C, Hadzik B, Abel M, Roth B: Renal failure associated with unrecognized hyperoncotic states after pediatric heart surgery. Intensive Care Med 1996; 22:492-4
94. Jungheinrich C, Scharpf R, Wargenau M, Bepperling F, Baron J-F: The pharmacokinetics and tolerability ofan intravenous infusion ofthe new hydroxy- ethyl starch 130/0.4 (6%, 50 0ml) in mild-to-severe renal impairment. Anesth Analg 2002; 95:544-51
95. Boldt J, Brosch C, Ducke M, Papsdorf M, Lehmann A: Influence of volume therapy with a modern hydroxyethylstarch preparation on kidney function in cardiac surgery patients with compromised renal function: A comparison with human albumin. Crit Care Med 2007; 35:2740-6
96. Fenger-Eriksen C, Hartig Rasmussen C, Kappel Jensen T, Anker-M0ller E, Heslop J, Fr0kiaer J, T0nnesen E: Renal effects of hypotensive anaesthesia in combination with acute normovolaemic haemodilution with hydroxyethyl starch 130/0.4 or isotonic saline. Acta Anaesthesiol Scand 2005; 49:969-74
97. Godet G, Lehat JJ, Janvier G, Steib A, de Castro V, Coriat P: Safety ofHES 130/0.4 (Voluven®) in patients with preoperative renal dysfunction undergong abdominal aortic surgery: A prospective, randomized, controlled, parallel-group multicentre trial. Eur J Anaesthesiol 2008; 25:986-94
98. Boldt J, Suttner S, Brosch C, Lehmann A, Roahm K, Mengistu A: The influence of a balanced volume replacement concept on inflammation, endothe- lial activation, and kidney integrity in elderly cardiac surgery patients. Intensive Care Med 2009; 35:462-70
99. Suampelmann R, Kretz FJ, Gaabler R, Luntzer R, Baroncini S, Osterkorn D, Haeger MC, Osthaus WA: Hydroxyethyl starch 130/0.42/6:1 for perioperative plasma volume replacement in children: Preliminary results of a European Prospective Multicenter Observational Postauthorization Safety Study (PASS). Paedi- atr Anaesth 2008; 18:929-33
100. Schortgen F, Girou E, Deye N, Brochard L: The risk associated with hyperoncotic colloids in patients with shock. Intensive Care Med 2008; 34:2157-68
101. Boldt J, Ducke M, Kumle B, Papsdorf M, Zurmeyer E: Influence of different volume replacement strategies on inflammation and endothelial activation in the elderly undergoing major abdominal surgery. Intensive Care Med 2004; 30:416-22
102. Boldt J, Schoalhorn T, Mayer J, Piper S, Suttner S: The value of an albumin-based intravascular volume replacement strategy in elderly patients undergoing major abdominal surgery. Anesth Analg 2006; 103:191-9
103. Boldt J, Brenner T, Lehmann A, Lang J, Kumle B, Werling C: Influence of two different volume replacement regimens on renal function in elderly patients undergoing cardiac surgery: Comparison of a new starch preparation with gelatin. Intensive Care Med 2003; 29:763-9
104. Boldt J, Suttner S: Plasma substitutes. Minerva Anesthesiol 2005; 71:741-58
105. Laxenaire M, Charpentier C, Feldman L, Le Group Francais d'Etude, de la Toleerance des Substituts Plasmatiques: Anaphylactoid reactions to colloid plasma substitutes: Frequency, risk factors, mechanisms. A French multicenter prospective study. Ann Fr Anesth Reeanim 1994; 13:301-10
106. Saudan S, Pellegrini M, Ceroni D, Kaelin A, Habre W: Hydroxyethyl starch 130/0.4 versus 5% human albumin in children undergoing spinal fusion: Safety and efficiency. Eur J Anaesthesiol 2006; 23:A-662
107. Mahmood A, Gosling P, Vohra RK: Randomized clinical trial comparing the effects on renal function of hydroxyethyl starch or gelatine during aortic aneurysm surgery. Br J Surg 2007; 94:427-33
108. ®) or human albumin in children younger than 2 yr undergoing non-cardiac surgery. A prospective, randomized, open label, multicentre trial. Eur J Anaesthesiol 2008; 25:437-45
109. Khalife M, Hanart C, de Ville A, de Hert S, van der Linden P: 6% HES 130/0.4 versus 4% albumin for volume replacementin paediatric cardiac surgery: Cyanotic congenital disease. Eur J Anaesthesiol 2006; 23:A-300
110. Hanart C, Khalife M, De Villee A, Otte F, De Hert S, Van der Linden P:Perioperative volume replacement in children undergoing cardiac surgery: Albumin versus hydroxyethyl starch 130/0.4. Crit Care Med 2009; 37:696-701
111. Lang K, Boldt J, Suttner S, Haisch G: Colloids versus crystalloids and tissue oxygen tension in patients undergoing major abdominal surgery. Anesth Analg 2001; 93:405-9
112. Standl T, Burmeister MA, Schroeder F, Currlin E, Schulte am Esch J, Freitag M, Schulte am Esch J: Hydroxyethyl starch (HES) 130/0.4 provides larger and faster increases in tissue oxygen tension in comparison with prehemodilution values than HES 70/0.5 or HES 200/0.5 in volunteers undergoing acute normovolemic hemodilution. Anesth Analg 2003; 96:936-43
113. Neff TA, Fischler L, Mark M, Stocker R, Reinhart WH: The influence of two different hydroxyethyl starch solutions (6% HES 130/0.4 and 200/0.5) on blood viscosity. Anesth Analg 2005; 100:1773-80
114. Kuntz C, Kienle P, Schmeding M, Benner A, Autschbach F, Schwalbach P: Comparison of laparoscopic versus conventional technique in colonic and liver resection in a tumor-bearingsmall animal model. SurgEndosc 2002; 16:1175-81
115. Sessler CN, Windsor AC, Schwartz M, Watson L, Fisher BJ, Sugerman HJ, Fowler AA 3rd: Circulating ICAM-1 is increased in septic shock. Am J Respir Crit Care Med 1995; 151:1420-7
116. Suffredini A: Current prospects for the treatment of clinical sepsis. Crit Care Med 1994; 22:S12-8
117. Meissner M, Tschaikowsky K, Hutzler A, Schlick C, Schuattler J: Postoperative plasma concentrations of prop-calcitonin after different types of surgery. Intensive Care Med 1998; 24:680-4
118. Rink L, Cakman I, Kirchner H: Altered cytokine production in the elderly.Mech Ageing Dev 1998; 102:199-209
119. Lang K, Suttner S, Boldt J, Kumle B, Nagel D: Volume replacement with HES 130/0.4 may reduce the inflammatory response in patients undergoing major abdominal surgery. Can J Anaesth 2003; 50:1009-16
120. Collis RE, Collins PW, Gutteridge CN, Kaul A, Newland AC, Williams DM, WebbAR: The effectofhydroxyethylstarchandotherplasmavolume substitutes on endothelial cell activation: An in vitro study. Intensive Care Med 1994; 20:37-41
121. Volta CA, Alvis V, Campi M, Marangoni E, Alvis R, Castellazzi M, Fainardi E, Manfrinato MC, Dallocchio F, Bellini T: Influence of different strategies of volume replacementonthe activityofmatrixmetalloproteinases: Aninvitro and in vivo study. ANESTHESIOLOGY 2007; 106:85-91
122. Dieterich H-J, Weissmualler T, Rosenberger P, Eltzschig HK: Effect of hydroxyethyl starch on vascular leak syndrome and neutrophil accumulation during hypoxia. Crit Care Med 2006; 34:1775-82
123. Nohee B, Johannes T, Reutershan J, Rothmund A, Haeberle H, Ploppa A, Schroeder T, Dieterich H-J: Synthetic colloids attenuate leukocyte-endothelial interactions by inhibition of integrin function. ANESTHESIOLOGY 2005; 103:759-67
124. Stephens R, Mythen M: Optimizing intraoperative fluid therapy. Curr opin Anaesthesiol 2003; 16:385-92
125. WilkesNJ, WoolfR, Mutch M, MallettSV, PeacheyT, Stephens R, Mythen MG: The effects of balanced versus saline-based hetastarch and crystalloid solutions on acid-base and electrolyte status and gastric mucosal perfusion in elderly surgical patients. Anesth Analg 2001; 93:811-6
126. McFarlane C, Lee A: A comparison of Plasmalyte 148 and 0.9% saline for intra-operative fluid replacement. Anaesthesia 1994; 49:779-81
127. Scheingraber S, Rehm M, Sehmisch C, Finsterer U: Rapid saline infusion produces hyperchloremic acidosis in patients undergoing gynaecologic surgery. ANESTHESIOLOGY 1999; 90:1265-70
128. Boldt J, Huattner I, Suttner S, Kumle B, Piper SN, Berchthold G: Changes of haemostasis in patients undergoing major abdominal surgery - Is there adifference between elderly and younger patients? Br J Anaesth 2001; 87:435-40
129. Haisch G, Boldt J, Krebs C, Kumle B, Suttner S, Schulz A: The influence of intravascular volume therapy wih a new hydroxyethyl starch preparation (6% HES 130/0.4) on coagulation in patients undergoing major abdominal surgery.Anesth Analg 2001; 92:565-71
130. Haisch G, Boldt J, Krebs C, Suttner S, Lehmann A, Isgro F: Influence of a new hydroxyethylstarch preparation (HES 130/0.4) on coagulation in cardiac surgical patients. J Cardiothorac Vasc Anesth 2001; 15:316-21
131. Mathes DD, Morell RC, Rohr MS: Dilutional acidosis: Is it a real clinical entity? ANESTHESIOLOGY 1997; 86:501-3
132. Williams EL, Hildebrand KL, McCormick SA, Bedel MJ: The effect of intravenous lactated Ringer's solution versus 0.9% sodium chloride solution on serum osmolality in human volunteers. Anesth Analg 1999; 88:999-1003
133. Prough DS, White RT: Acidosis associated with perioperative saline administration: Dilution or delusion? ANESTHESIOLOGY 2000; 93:1167-9
134. Boldt J, Mengistu A, Seyfert UT, Vogt A, Hellstern P: The impact of a medium molecular weight, low molar substitution hydroxyethyl starch dissolved in a physiologically balanced electrolyte solution on blood coagulation and platelet function in vitro. Vox Sang 2007; 93:139-44
135. Boldt J, Wolf M, Mengistu A: A new plasma-adapted hydroxyethylstarch preparation: In vitro coagulation studies using thrombelastography and whole blood aggregometry. Anesth Analg 2007; 104:425-30
136. BoldtJ, SchoallhornT, Muanchbach J, PabsdorfM: Atotalbalancedvolume replacement strategy using a new balanced hydroxyethyl starch preparation (6% HES 130/0.42) in patients undergoing major abdominal surgery. Eur J Anaesthe- siol 2007; 24:267-75
137. Base E, Standl T, Lassnigg A, Mahl C, Jungheinrich C: Comparison of 6% HES 130/0.4 in a balanced electrolyte solution versus 6% HES 130/0.4 in saline solution in cardiac surgery. Crit Care 2006; 10:P176
138. Jungheinrich C, Neff TA: Pharmacokinetics of hydroxyethyl starch. Clin Pharmacokinet 2005; 44:681-99
139. Asskali F, Warnken U, Foarster H: Acetylstaarke als Volumenersatz, eine Moagliche Alternative zu HES. Dtsch Med Wochenschr 2001; 126:1-6
140. Lehmann GB, Asskali F, Boll M, Burmeister MA, Marx G, Hilgers R, Foerster H: HES 130/0.42 shows less alteration of pharmacokinetics than HES 200/0.5 when dosed repeatedly. Br J Anaesth 2007; 98:635-44